- Home
- PCRX vs RGR Comparison
PCRX vs RGR Comparison
Compare PCRX & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- RGR
- Stock Information
- Founded
- PCRX 2006
- RGR 1949
- Country
- PCRX United States
- RGR United States
- Employees
- PCRX N/A
- RGR N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- RGR Ordnance And Accessories
- Sector
- PCRX Health Care
- RGR Industrials
- Exchange
- PCRX Nasdaq
- RGR Nasdaq
- Market Cap
- PCRX 1.2B
- RGR 616.8M
- IPO Year
- PCRX 2011
- RGR N/A
- Fundamental
- Price
- PCRX $23.22
- RGR $36.52
- Analyst Decision
- PCRX Buy
- RGR
- Analyst Count
- PCRX 8
- RGR 0
- Target Price
- PCRX $28.38
- RGR N/A
- AVG Volume (30 Days)
- PCRX 569.8K
- RGR 195.7K
- Earning Date
- PCRX 07-29-2025
- RGR 07-30-2025
- Dividend Yield
- PCRX N/A
- RGR 1.92%
- EPS Growth
- PCRX N/A
- RGR N/A
- EPS
- PCRX N/A
- RGR 1.83
- Revenue
- PCRX $702,772,000.00
- RGR $534,561,000.00
- Revenue This Year
- PCRX $7.54
- RGR N/A
- Revenue Next Year
- PCRX $10.78
- RGR $1.89
- P/E Ratio
- PCRX N/A
- RGR $19.94
- Revenue Growth
- PCRX 3.08
- RGR 0.65
- 52 Week Low
- PCRX $11.16
- RGR $32.74
- 52 Week High
- PCRX $27.64
- RGR $46.40
- Technical
- Relative Strength Index (RSI)
- PCRX 35.42
- RGR 49.99
- Support Level
- PCRX $22.82
- RGR $35.53
- Resistance Level
- PCRX $24.36
- RGR $36.64
- Average True Range (ATR)
- PCRX 0.69
- RGR 0.76
- MACD
- PCRX -0.12
- RGR -0.03
- Stochastic Oscillator
- PCRX 17.09
- RGR 42.53
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About RGR Sturm Ruger & Company Inc.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.